ClinicalTrials.govpublic full text
Adjuvant Targeted-therapy for Patients With Resected High-risk EGFR-mutant Stage IB-IIA Non-small Cell Lung Carcinoma
nsclc, egf-r positive non-small cell lung cancer, egfr mutation, adjuvant therapy, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 826826
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.